Q4 2025 BioLife Solutions Inc Earnings Call Transcript
Key Points
- BioLife Solutions Inc (BLFS) reported a 29% increase in total revenue for 2025, reaching $96 million, which was at the high end of their guidance.
- The company achieved a significant increase in adjusted EBITDA, reaching $25 million or 26% of revenue, up from $13 million or 18% in 2024.
- BioLife Solutions Inc (BLFS) has a strong position in the CGT market, with their BPM products embedded in 16 approved therapies and utilized in over 250 commercially sponsored CGT trials in the US.
- The company anticipates up to five unique therapy approvals over the next 12 months, which could drive further growth.
- BioLife Solutions Inc (BLFS) has entered into a strategic distribution and product development agreement with UK-based Quine Limited, expanding their product offerings and market reach.
- Gross margins declined year-over-year due to product mix and lower bag yields, impacting profitability.
- The HPL media business was flat year-over-year due to import restrictions in China, which have since been resolved.
- The company faces challenges with bag yields, which are expected to impact gross margins until at least Q4 2026.
- There is limited visibility into the impact of recent regulatory changes on patient access and revenue growth in the CAR-T market.
- BioLife Solutions Inc (BLFS) is not seeing significant uptake in clinical trial activity despite positive biotech funding data, indicating potential challenges in the clinical segment.
Good afternoon, ladies and gentlemen and thank you for standing by. Welcome to the Biolife Solutions Q4 2025 shareholder and analyst conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. I would now like to turn the call over to Troy Wichterman, Chief Financial Officer of BioLife Solutions. Please go ahead.
Thank you, operator Good afternoon, everyone, and thank you for joining the Biolife Solutions 2025, fourth quarter earnings conference call. On this call, we will cover business highlights, financial performance for the fourth quarter in full year 2025 and provide 2026 financial guidance. Earlier today, we issued a press release announcing our financial results and operational highlights for the fourth quarter and fourth year of 2025 and provided 2026 financial guidance, which is available at biolifesolutions.com.
As a reminder, during this call, we will make forward-looking statements.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
